Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a report on Friday, June 14th. Canaccord Genuity Group cut their price objective on Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a report on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $14.80.

Aptose Biosciences Price Performance

Shares of Aptose Biosciences stock opened at $0.38 on Monday. Aptose Biosciences has a 52 week low of $0.35 and a 52 week high of $4.15. The business’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $1.05. The firm has a market cap of $6.85 million, a PE ratio of -0.06 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.15. As a group, equities analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.